1. Home
  2. UPBD vs ADPT Comparison

UPBD vs ADPT Comparison

Compare UPBD & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UPBD
  • ADPT
  • Stock Information
  • Founded
  • UPBD 1986
  • ADPT 2009
  • Country
  • UPBD United States
  • ADPT United States
  • Employees
  • UPBD N/A
  • ADPT N/A
  • Industry
  • UPBD Diversified Commercial Services
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • UPBD Consumer Discretionary
  • ADPT Health Care
  • Exchange
  • UPBD Nasdaq
  • ADPT Nasdaq
  • Market Cap
  • UPBD 1.2B
  • ADPT 1.4B
  • IPO Year
  • UPBD 1995
  • ADPT 2019
  • Fundamental
  • Price
  • UPBD $23.30
  • ADPT $9.55
  • Analyst Decision
  • UPBD Buy
  • ADPT Buy
  • Analyst Count
  • UPBD 5
  • ADPT 6
  • Target Price
  • UPBD $36.60
  • ADPT $9.83
  • AVG Volume (30 Days)
  • UPBD 454.3K
  • ADPT 1.8M
  • Earning Date
  • UPBD 07-31-2025
  • ADPT 05-01-2025
  • Dividend Yield
  • UPBD 6.76%
  • ADPT N/A
  • EPS Growth
  • UPBD N/A
  • ADPT N/A
  • EPS
  • UPBD 2.13
  • ADPT N/A
  • Revenue
  • UPBD $4,400,960,000.00
  • ADPT $189,527,000.00
  • Revenue This Year
  • UPBD $10.08
  • ADPT $25.00
  • Revenue Next Year
  • UPBD $7.72
  • ADPT $20.38
  • P/E Ratio
  • UPBD $10.86
  • ADPT N/A
  • Revenue Growth
  • UPBD 8.07
  • ADPT 8.61
  • 52 Week Low
  • UPBD $19.69
  • ADPT $2.99
  • 52 Week High
  • UPBD $38.72
  • ADPT $10.28
  • Technical
  • Relative Strength Index (RSI)
  • UPBD 49.10
  • ADPT 60.50
  • Support Level
  • UPBD $22.53
  • ADPT $8.50
  • Resistance Level
  • UPBD $23.46
  • ADPT $9.69
  • Average True Range (ATR)
  • UPBD 0.63
  • ADPT 0.42
  • MACD
  • UPBD -0.20
  • ADPT -0.00
  • Stochastic Oscillator
  • UPBD 21.45
  • ADPT 81.40

About UPBD Upbound Group Inc.

Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has three operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions across e-commerce, digital, and mobile channels, Mexico segment offers lease-to-own stores in Mexico. The franchising segment offers the sale of rental merchandise to its franchisees. The company derives a majority of its revenue from the Acima segment.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Share on Social Networks: